The extracellular matrix in breast cancer

Advanced Drug Delivery Reviews

Volumn 97, Issue , 2016, Pages 41-55

  Insua Rodríguez, Jacob ^a,b   Oskarsson, Thordur ^a,b  

^a Hi STEM Heidelberg Institute for Stem Cell Technology and Experimental Medicine GmbH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Breast cancer; Extracellular matrix; Metastasis; Niche; Therapy

Indexed keywords

ENZYME INHIBITION; ENZYMES; PATHOLOGY; PHYSIOLOGY; PROTEINS; TISSUE; TISSUE HOMEOSTASIS; TISSUE REGENERATION;

BREAST CANCER; EXTRACELLULAR MATRICES; METASTASIS; NICHE; THERAPY;

DISEASES;

AFG 495; CATHEPSIN; COLLAGEN; DECORIN; DX 2400; FIBRONECTIN; GLYPICAN; HEPARANASE; HYALURONIC ACID; HYMECROMONE; L 235; LAMININ; LUMICAN; MATRIX METALLOPROTEINASE; MATRIX PROTEIN; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; ODANACATIB; OSTEONECTIN; OSTEOPONTIN; PROTEIN LYSINE 6 OXIDASE; PROTEOGLYCAN; RECOMBINANT ENDOSTATIN; SCLEROPROTEIN; SYNDECAN; TENASCIN; THROMBOSPONDIN; TRANSCRIPTION FACTOR RUNX2; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; VERSICAN;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER INHIBITION; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; LUNG METASTASIS; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TISSUE REGENERATION; ANIMAL; BREAST NEOPLASMS; FEMALE; METABOLISM;

ANIMALS; BREAST NEOPLASMS; EXTRACELLULAR MATRIX; FEMALE; HUMANS;

EID: 84955495692     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2015.12.017     Document Type: Review

References (230)

1. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J. Clin. 2015, 65:87-108.
2. Oskarsson T., Batlle E., Massague J. Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell 2014, 14:306-321.
3. Bissell M.J., Hines W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 2011, 17:320-329.
4. Pein M., Oskarsson T. Microenvironment in metastasis: roadblocks and supportive niches. Am. J. Physiol. Cell Physiol. 2015, 309:C627-C638.
5. Oskarsson T. Extracellular matrix components in breast cancer progression and metastasis. Breast 2013, 22(Suppl. 2):S66-S72.
6. Muschler J., Streuli C.H. Cell-matrix interactions in mammary gland development and breast cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a003202.
7. Lochter A., Bissell M.J. Involvement of extracellular matrix constituents in breast cancer. Semin. Cancer Biol. 1995, 6:165-173.
8. Lu P., Takai K., Weaver V.M., Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb. Perspect. Biol. 2011, 3.
9. Schedin P., O'Brien J., Rudolph M., Stein T., Borges V. Microenvironment of the involuting mammary gland mediates mammary cancer progression. J. Mammary Gland Biol. Neoplasia 2007, 12:71-82.
10. O'Brien J.H., Vanderlinden L.A., Schedin P.J., Hansen K.C. Rat mammary extracellular matrix composition and response to ibuprofen treatment during postpartum involution by differential GeLC-MS/MS analysis. J. Proteome Res. 2012, 11:4894-4905.
11. Schedin P. Pregnancy-associated breast cancer and metastasis. Nat. Rev. Cancer 2006, 6:281-291.
12. Lyons T.R., O'Brien J., Borges V.F., Conklin M.W., Keely P.J., Eliceiri K.W., Marusyk A., Tan A.C., Schedin P. Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nat. Med. 2011, 17:1109-1115.
13. McDaniel S.M., Rumer K.K., Biroc S.L., Metz R.P., Singh M., Porter W., Schedin P. Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am. J. Pathol. 2006, 168:608-620.
14. Naba A., Clauser K.R., Lamar J.M., Carr S.A., Hynes R.O. Extracellular matrix signatures of human mammary carcinoma identify novel metastasis promoters. eLife 2014, 3.
15. Bergamaschi A., Tagliabue E., Sorlie T., Naume B., Triulzi T., Orlandi R., Russnes H.G., Nesland J.M., Tammi R., Auvinen P., Kosma V.M., Menard S., Borresen-Dale A.L. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome. Am. J. Pathol. 2008, 214:357-367.
16. Egeblad M., Rasch M.G., Weaver V.M. Dynamic interplay between the collagen scaffold and tumor evolution. Curr. Opin. Cell Biol. 2010, 22:697-706.
17. Tavazoie S.F., Alarcon C., Oskarsson T., Padua D., Wang Q., Bos P.D., Gerald W.L., Massague J. Endogenous human microRNAs that suppress breast cancer metastasis. Nature 2008, 451:147-152.
18. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 2003, 33:49-54.
19. Kauppila S., Stenback F., Risteli J., Jukkola A., Risteli L. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J. Pathol. 1998, 186:262-268.
20. Hasebe T., Sasaki S., Imoto S., Mukai K., Yokose T., Ochiai A. Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study Modern pathology. Off. J. U. S. Can. Acad. Pathol. Inc. 2002, 15:502-516.
21. Wyckoff J.B., Wang Y., Lin E.Y., Li J.F., Goswami S., Stanley E.R., Segall J.E., Pollard J.W., Condeelis J. Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. Cancer Res. 2007, 67:2649-2656.
22. Kadler K.E., Hill A., Canty-Laird E.G. Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr. Opin. Cell Biol. 2008, 20:495-501.
23. Provenzano P.P., Inman D.R., Eliceiri K.W., Knittel J.G., Yan L., Rueden C.T., White J.G., Keely P.J. Collagen density promotes mammary tumor initiation and progression. BMC Med. 2008, 6:11.
24. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., Fong S.F., Csiszar K., Giaccia A., Weninger W., Yamauchi M., Gasser D.L., Weaver V.M. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
25. Boyd N.F., Martin L.J., Yaffe M.J., Minkin S. Mammographic density and breast cancer risk: current understanding and future prospects. Breast Cancer Res. BCR 2011, 13:223.
26. Seo B.R., Bhardwaj P., Choi S., Gonzalez J., Andresen Eguiluz R.C., Wang K., Mohanan S., Morris P.G., Du B., Zhou X.K., Vahdat L.T., Verma A., Elemento O., Hudis C.A., Williams R.M., Gourdon D., Dannenberg A.J., Fischbach C. Obesity-dependent changes in interstitial ECM mechanics promote breast tumorigenesis. Sci. Transl. Med. 2015, 7. (301ra130).
27. Provenzano P.P., Inman D.R., Eliceiri K.W., Keely P.J. Matrix density-induced mechanoregulation of breast cell phenotype, signaling and gene expression through a FAK-ERK linkage. Oncogene 2009, 28:4326-4343.
28. Choquet D., Felsenfeld D.P., Sheetz M.P. Extracellular matrix rigidity causes strengthening of integrin-cytoskeleton linkages. Cell 1997, 88:39-48.
29. Wozniak M.A., Desai R., Solski P.A., Der C.J., Keely P.J. ROCK-generated contractility regulates breast epithelial cell differentiation in response to the physical properties of a three-dimensional collagen matrix. J. Cell Biol. 2003, 163:583-595.
30. Klein E.A., Yin L., Kothapalli D., Castagnino P., Byfield F.J., Xu T., Levental I., Hawthorne E., Janmey P.A., Assoian R.K. Cell-cycle control by physiological matrix elasticity and in vivo tissue stiffening. Curr. Biol. CB 2009, 19:1511-1518.
31. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., Reinhart-King C.A., Margulies S.S., Dembo M., Boettiger D., Hammer D.A., Weaver V.M. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
32. Dupont S., Morsut L., Aragona M., Enzo E., Giulitti S., Cordenonsi M., Zanconato F., Le Digabel J., Forcato M., Bicciato S., Elvassore N., Piccolo S. Role of YAP/TAZ in mechanotransduction. Nature 2011, 474:179-183.
33. Cordenonsi M., Zanconato F., Azzolin L., Forcato M., Rosato A., Frasson C., Inui M., Montagner M., Parenti A.R., Poletti A., Daidone M.G., Dupont S., Basso G., Bicciato S., Piccolo S. The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 2011, 147:759-772.
34. Barkan D., El Touny L.H., Michalowski A.M., Smith J.A., Chu I., Davis A.S., Webster J.D., Hoover S., Simpson R.M., Gauldie J., Green J.E. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 2010, 70:5706-5716.
35. Parekh A., Ruppender N.S., Branch K.M., Sewell-Loftin M.K., Lin J., Boyer P.D., Candiello J.E., Merryman W.D., Guelcher S.A., Weaver A.M. Sensing and modulation of invadopodia across a wide range of rigidities. Biophys. J. 2011, 100:573-582.
36. Hayashi M., Yamamoto Y., Ibusuki M., Fujiwara S., Yamamoto S., Tomita S., Nakano M., Murakami K., Iyama K., Iwase H. Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. Ann. Surg. Oncol. 2012, 19:3042-3049.
37. Sottile J., Hocking D.C. Fibronectin polymerization regulates the composition and stability of extracellular matrix fibrils and cell-matrix adhesions. Mol. Biol. Cell 2002, 13:3546-3559.
38. Tse J.M., Cheng G., Tyrrell J.A., Wilcox-Adelman S.A., Boucher Y., Jain R.K., Munn L.L. Mechanical compression drives cancer cells toward invasive phenotype. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:911-916.
39. Qian P., Zuo Z., Wu Z., Meng X., Li G., Wu Z., Zhang W., Tan S., Pandey V., Yao Y., Wang P., Zhao L., Wang J., Wu Q., Song E., Lobie P.E., Yin Z., Zhu T. Pivotal role of reduced let-7g expression in breast cancer invasion and metastasis. Cancer Res. 2011, 71:6463-6474.
40. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., MacDonald D.D., Jin D.K., Shido K., Kerns S.A., Zhu Z., Hicklin D., Wu Y., Port J.L., Altorki N., Port E.R., Ruggero D., Shmelkov S.V., Jensen K.K., Rafii S., Lyden D. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
41. Fernandez-Garcia B., Eiro N., Marin L., Gonzalez-Reyes S., Gonzalez L.O., Lamelas M.L., Vizoso F.J. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology 2014, 64:512-522.
42. Bae Y.K., Kim A., Kim M.K., Choi J.E., Kang S.H., Lee S.J. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer. Hum. Pathol. 2013, 44:2028-2037.
43. Raimondi C., Gradilone A., Naso G., Vincenzi B., Petracca A., Nicolazzo C., Palazzo A., Saltarelli R., Spremberg F., Cortesi E., Gazzaniga P. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res. Treat. 2011, 130:449-455.
44. Yu M., Bardia A., Wittner B.S., Stott S.L., Smas M.E., Ting D.T., Isakoff S.J., Ciciliano J.C., Wells M.N., Shah A.M., Concannon K.F., Donaldson M.C., Sequist L.V., Brachtel E., Sgroi D., Baselga J., Ramaswamy S., Toner M., Haber D.A., Maheswaran S. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339:580-584.
45. Park J., Schwarzbauer J.E. Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition. Oncogene 2014, 33:1649-1657.
46. Balanis N., Wendt M.K., Schiemann B.J., Wang Z., Schiemann W.P., Carlin C.R. Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J. Biol. Chem. 2013, 288:17954-17967.
47. McIntosh J., Dennison G., Holly J.M., Jarrett C., Frankow A., Foulstone E.J., Winters Z.E., Perks C.M. IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin. J. Biol. Chem. 2010, 285:38788-38800.
48. Patarroyo M., Tryggvason K., Virtanen I. Laminin isoforms in tumor invasion, angiogenesis and metastasis. Semin. Cancer Biol. 2002, 12:197-207.
49. Streuli C.H., Edwards G.M. Control of normal mammary epithelial phenotype by integrins. J. Mammary Gland Biol. Neoplasia 1998, 3:151-163.
50. Streuli C.H., Edwards G.M., Delcommenne M., Whitelaw C.B., Burdon T.G., Schindler C., Watson C.J. Stat5 as a target for regulation by extracellular matrix. J. Biol. Chem. 1995, 270:21639-21644.
51. Gudjonsson T., Ronnov-Jessen L., Villadsen R., Rank F., Bissell M.J., Petersen O.W. Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition. J. Cell Sci. 2002, 115:39-50.
52. Benton G., Crooke E., George J. Laminin-1 induces E-cadherin expression in 3-dimensional cultured breast cancer cells by inhibiting DNA methyltransferase 1 and reversing promoter methylation status. FASEB J. Off. Public. Fed. Am. Soc. Exp. Biol. 2009, 23:3884-3895.
53. Zahir N., Lakins J.N., Russell A., Ming W., Chatterjee C., Rozenberg G.I., Marinkovich M.P., Weaver V.M. Autocrine laminin-5 ligates alpha6beta4 integrin and activates RAC and NFkappaB to mediate anchorage-independent survival of mammary tumors. J. Cell Biol. 2003, 163:1397-1407.
54. Kwon S.Y., Chae S.W., Wilczynski S.P., Arain A., Carpenter M., Philip L. 332 expression in breast carcinoma, applied immunohistochemistry & molecular morphology. AIMM/Off. Public. Soc. Appl. Immunohistochem. 2012, 20:159-164.
55. Carpenter P.M., Dao A.V., Arain Z.S., Chang M.K., Nguyen H.P., Arain S., Wang-Rodriguez J., Kwon S.Y., Wilczynski S.P. Motility induction in breast carcinoma by mammary epithelial laminin 332 (laminin 5). Mol. Cancer Res. MCR 2009, 7:462-475.
56. Kim B.G., An H.J., Kang S., Choi Y.P., Gao M.Q., Park H., Cho N.H. Laminin-332-rich tumor microenvironment for tumor invasion in the interface zone of breast cancer. Am. J. Pathol. 2011, 178:373-381.
57. Kim B.G., Gao M.Q., Choi Y.P., Kang S., Park H.R., Kang K.S., Cho N.H. Invasive breast cancer induces laminin-332 upregulation and integrin beta4 neoexpression in myofibroblasts to confer an anoikis-resistant phenotype during tissue remodeling. Breast Cancer Res. BCR 2012, 14:R88.
58. Chia J., Kusuma N., Anderson R., Parker B., Bidwell B., Zamurs L., Nice E., Pouliot N. Evidence for a role of tumor-derived laminin-511 in the metastatic progression of breast cancer. Am. J. pathol. 2007, 170:2135-2148.
59. Kusuma N., Denoyer D., Eble J.A., Redvers R.P., Parker B.S., Pelzer R., Anderson R.L., Pouliot N. Integrin-dependent response to laminin-511 regulates breast tumor cell invasion and metastasis. Int. J. Cancer. J. Int. Cancer 2012, 130:555-566.
60. Chang C., Goel H.L., Gao H., Pursell B., Shultz L.D., Greiner D.L., Ingerpuu S., Patarroyo M., Cao S., Lim E., Mao J., McKee K.K., Yurchenco P.D., Mercurio A.M. A laminin 511 matrix is regulated by TAZ and functions as the ligand for the alpha6Bbeta1 integrin to sustain breast cancer stem cells. Genes Dev. 2015, 29:1-6.
61. Rodin S., Domogatskaya A., Strom S., Hansson E.M., Chien K.R., Inzunza J., Hovatta O., Tryggvason K. Long-term self-renewal of human pluripotent stem cells on human recombinant laminin-511. Nat. Biotechnol. 2010, 28:611-615.
62. Ross J.B., Huh D., Noble L.B., Tavazoie S.F. Identification of molecular determinants of primary and metastatic tumour re-initiation in breast cancer. Nat. Cell Biol. 2015, 17:651-664.
63. Karousou E., D'Angelo M.L., Kouvidi K., Vigetti D., Viola M., Nikitovic D., De Luca G., Passi A. Collagen VI and hyaluronan: the common role in breast cancer. BioMed. Res. Int. 2014, 2014:606458.
64. Toole B.P. Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 2004, 4:528-539.
65. Wang Z., Wu Y., Wang H., Zhang Y., Mei L., Fang X., Zhang X., Zhang F., Chen H., Liu Y., Jiang Y., Sun S., Zheng Y., Li N., Huang L. Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:E89-E98.
66. Hamilton S.R., Fard S.F., Paiwand F.F., Tolg C., Veiseh M., Wang C., McCarthy J.B., Bissell M.J., Koropatnick J., Turley E.A. The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J. Biol. Chem. 2007, 282:16667-16680.
67. Delpech B., Chevallier B., Reinhardt N., Julien J.P., Duval C., Maingonnat C., Bastit P., Asselain B. Serum hyaluronan (hyaluronic acid) in breast cancer patients. Int. J. Cancer J. Int. Cancer 1990, 46:388-390.
68. Vigetti D., Clerici M., Deleonibus S., Karousou E., Viola M., Moretto P., Heldin P., Hascall V.C., De Luca G., Passi A. Hyaluronan synthesis is inhibited by adenosine monophosphate-activated protein kinase through the regulation of HAS2 activity in human aortic smooth muscle cells. J. Biol. Chem. 2011, 286:7917-7924.
69. Vigetti D., Deleonibus S., Moretto P., Karousou E., Viola M., Bartolini B., Hascall V.C., Tammi M., De Luca G., Passi A. Role of UDP-N-acetylglucosamine (GlcNAc) and O-GlcNAcylation of hyaluronan synthase 2 in the control of chondroitin sulfate and hyaluronan synthesis. J. Biol. Chem. 2012, 287:35544-35555.
70. Okuda H., Kobayashi A., Xia B., Watabe M., Pai S.K., Hirota S., Xing F., Liu W., Pandey P.R., Fukuda K., Modur V., Ghosh A., Wilber A., Watabe K. Hyaluronan synthase HAS2 promotes tumor progression in bone by stimulating the interaction of breast cancer stem-like cells with macrophages and stromal cells. Cancer Res. 2012, 72:537-547.
71. Auvinen P., Rilla K., Tumelius R., Tammi M., Sironen R., Soini Y., Kosma V.M., Mannermaa A., Viikari J., Tammi R. Hyaluronan synthases (HAS1-3) in stromal and malignant cells correlate with breast cancer grade and predict patient survival. Breast Cancer Res. Treat. 2014, 143:277-286.
72. Udabage L., Brownlee G.R., Waltham M., Blick T., Walker E.C., Heldin P., Nilsson S.K., Thompson E.W., Brown T.J. Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res. 2005, 65:6139-6150.
73. Koyama H., Hibi T., Isogai Z., Yoneda M., Fujimori M., Amano J., Kawakubo M., Kannagi R., Kimata K., Taniguchi S., Itano N. Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am. J. Pathol. 2007, 170:1086-1099.
74. Porsch H., Bernert B., Mehic M., Theocharis A.D., Heldin C.H., Heldin P. Efficient TGFbeta-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2. Oncogene 2013, 32:4355-4365.
75. Wu M., Cao M., He Y., Liu Y., Yang C., Du Y., Wang W., Gao F. A novel role of low molecular weight hyaluronan in breast cancer metastasis. FASEB J. Off. Public Fed. Am. Soc. Exp. Biol. 2015, 29:1290-1298.
76. Theocharis A.D., Skandalis S.S., Neill T., Multhaupt H.A., Hubo M., Frey H., Gopal S., Gomes A., Afratis N., Lim H.C., Couchman J.R., Filmus J., Sanderson R.D., Schaefer L., Iozzo R.V., Karamanos N.K. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim. Biophys. Acta 2015, 1855:276-300.
77. Kischel P., Waltregny D., Dumont B., Turtoi A., Greffe Y., Kirsch S., De Pauw E., Castronovo V. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int. J. Cancer J. Int. Cancer 2010, 126:640-650.
78. Ricciardelli C., Brooks J.H., Suwiwat S., Sakko A.J., Mayne K., Raymond W.A., Seshadri R., LeBaron R.G., Horsfall D.J. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2002, 8:1054-1060.
79. Yee A.J., Akens M., Yang B.L., Finkelstein J., Zheng P.S., Deng Z., Yang B. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res. BCR 2007, 9:R47.
80. Du W.W., Fang L., Yang X., Sheng W., Yang B.L., Seth A., Zhang Y., Yang B.B., Yee A.J. The role of versican in modulating breast cancer cell self-renewal. Mol. Cancer Res. MCR 2013, 11:443-455.
81. Nastase M.V., Iozzo R.V., Schaefer L. Key roles for the small leucine-rich proteoglycans in renal and pulmonary pathophysiology. Biochim. Biophys. Acta 2014, 1840:2460-2470.
82. Neill T., Schaefer L., Iozzo R.V. Decorin: a guardian from the matrix. Am. J. Pathol. 2012, 181:380-387.
83. Oda G., Sato T., Ishikawa T., Kawachi H., Nakagawa T., Kuwayama T., Ishiguro M., Iida S., Uetake H., Sugihara K. Significance of stromal decorin expression during the progression of breast cancer. Oncol. Rep. 2012, 28:2003-2008.
84. Eshchenko T.Y., Rykova V.I., Chernakov A.E., Sidorov S.V., Grigorieva E.V. Expression of different proteoglycans in human breast tumors. Biokhimiya/Biochemistry 2007, 72:1016-1020.
85. Leygue E., Snell L., Dotzlaw H., Troup S., Hiller-Hitchcock T., Murphy L.C., Roughley P.J., Watson P.H. Lumican and decorin are differentially expressed in human breast carcinoma. J. Pathol. 2000, 192:313-320.
86. Iozzo R.V., Moscatello D.K., McQuillan D.J., Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J. Biol. Chem. 1999, 274:4489-4492.
87. Santra M., Eichstetter I., Iozzo R.V. An anti-oncogenic role for decorin. Down-regulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J. Biol. Chem. 2000, 275:35153-35161.
88. Goldoni S., Seidler D.G., Heath J., Fassan M., Baffa R., Thakur M.L., Owens R.T., McQuillan D.J., Iozzo R.V. An antimetastatic role for decorin in breast cancer. Am. J. Pathol. 2008, 173:844-855.
89. Reed C.C., Waterhouse A., Kirby S., Kay P., Owens R.T., McQuillan D.J., Iozzo R.V. Decorin prevents metastatic spreading of breast cancer. Oncogene 2005, 24:1104-1110.
90. Araki K., Wakabayashi H., Shintani K., Morikawa J., Matsumine A., Kusuzaki K., Sudo A., Uchida A. Decorin suppresses bone metastasis in a breast cancer cell line. Oncology 2009, 77:92-99.
91. Soria-Valles C., Gutierrez-Fernandez A., Guiu M., Mari B., Fueyo A., Gomis R.R., Lopez-Otin C. The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21. Oncogene 2014, 33:3054-3063.
92. Neill T., Torres A., Buraschi S., Owens R.T., Hoek J.B., Baffa R., Iozzo R.V. Decorin induces mitophagy in breast carcinoma cells via peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) and mitostatin. J. Biol. Chem. 2014, 289:4952-4968.
93. Troup S., Njue C., Kliewer E.V., Parisien M., Roskelley C., Chakravarti S., Roughley P.J., Murphy L.C., Watson P.H. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2003, 9:207-214.
94. Leygue E., Snell L., Dotzlaw H., Hole K., Hiller-Hitchcock T., Roughley P.J., Watson P.H., Murphy L.C. Expression of lumican in human breast carcinoma. Cancer Res. 1998, 58:1348-1352.
95. Sharma B., Ramus M.D., Kirkwood C.T., Sperry E.E., Chu P.H., Kao W.W., Albig A.R. Lumican exhibits anti-angiogenic activity in a context specific manner. Cancer Microenviron. Off. J. Int. Cancer Microenviron. Soc. 2013, 6:263-271.
96. Hacker U., Nybakken K., Perrimon N. Heparan sulphate proteoglycans: the sweet side of development. Nat. Rev. Mol. Cell Biol. 2005, 6:530-541.
97. Stanley M.J., Stanley M.W., Sanderson R.D., Zera R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am. J. Clin. Pathol. 1999, 112:377-383.
98. Maeda T., Alexander C.M., Friedl A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 2004, 64:612-621.
99. Leivonen M., Lundin J., Nordling S., von Boguslawski K., Haglund C. Prognostic value of syndecan-1 expression in breast cancer. Oncology 2004, 67:11-18.
100. Barbareschi M., Maisonneuve P., Aldovini D., Cangi M.G., Pecciarini L., Angelo Mauri F., Veronese S., Caffo O., Lucenti A., Palma P.D., Galligioni E., Doglioni C. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 2003, 98:474-483.
101. Gotte M., Kersting C., Ruggiero M., Tio J., Tulusan A.H., Kiesel L., Wulfing P. Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res. 2006, 26:621-627.
102. Maeda T., Desouky J., Friedl A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 2006, 25:1408-1412.
103. Yang N., Mosher R., Seo S., Beebe D., Friedl A. Syndecan-1 in breast cancer stroma fibroblasts regulates extracellular matrix fiber organization and carcinoma cell motility. Am. J. Pathol. 2011, 178:325-335.
104. Burbach B.J., Ji Y., Rapraeger A.C. Syndecan-1 ectodomain regulates matrix-dependent signaling in human breast carcinoma cells. Exp. Cell Res. 2004, 300:234-247.
105. Beauvais D.M., Burbach B.J., Rapraeger A.C. The syndecan-1 ectodomain regulates alphavbeta3 integrin activity in human mammary carcinoma cells. J. Cell Biol. 2004, 167:171-181.
106. Ibrahim S.A., Hassan H., Vilardo L., Kumar S.K., Kumar A.V., Kelsch R., Schneider C., Kiesel L., Eich H.T., Zucchi I., Reinbold R., Greve B., Gotte M. Syndecan-1 (CD138) modulates triple-negative breast cancer stem cell properties via regulation of LRP-6 and IL-6-mediated STAT3 signaling. PLoS One 2013, 8.
107. Matsuda K., Maruyama H., Guo F., Kleeff J., Itakura J., Matsumoto Y., Lander A.D., Korc M. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001, 61:5562-5569.
108. Xiang Y.Y., Ladeda V., Filmus J. Glypican-3 expression is silenced in human breast cancer. Oncogene 2001, 20:7408-7412.
109. Peters M.G., Farias E., Colombo L., Filmus J., Puricelli L., Bal de Kier Joffe E. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res. Treat. 2003, 80:221-232.
110. Buchanan C., Stigliano I., Garay-Malpartida H.M., Rodrigues Gomes L., Puricelli L., Sogayar M.C., Bal de Kier Joffe E., Peters M.G. Glypican-3 reexpression regulates apoptosis in murine adenocarcinoma mammary cells modulating PI3K/Akt and p38MAPK signaling pathways. Breast Cancer Res. Treat. 2010, 119:559-574.
111. Murphy-Ullrich J.E., Sage E.H. Revisiting the matricellular concept. Matrix Biol. J. Int. Soc. Matrix Biol. 2014, 37:1-14.
112. Murphy-Ullrich J.E. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state?. J. Clin. Investig. 2001, 107:785-790.
113. Chong H.C., Tan C.K., Huang R.L., Tan N.S. Matricellular proteins: a sticky affair with cancers. J. Oncol. 2012, 2012:351089.
114. Wong G.S., Rustgi A.K. Matricellular proteins: priming the tumour microenvironment for cancer development and metastasis. B. J. Cancer 2013, 108:755-761.
115. Oskarsson T., Acharyya S., Zhang X.H., Vanharanta S., Tavazoie S.F., Morris P.G., Downey R.J., Manova-Todorova K., Brogi E., Massague J. Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat. Med. 2011, 17:867-874.
116. Malanchi I., Santamaria-Martinez A., Susanto E., Peng H., Lehr H.A., Delaloye J.F., Huelsken J. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
117. Tuck A.B., Chambers A.F. The role of osteopontin in breast cancer: clinical and experimental studies. J. Mammary Gland Biol. Neoplasia 2001, 6:419-429.
118. Shevde L.A., Samant R.S. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. J. Int. Soc. Matrix Biol. 2014, 37:131-141.
119. Rittling S.R., Novick K.E. Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ. Mol. Biol. J. Am. Assoc. Cancer Res. 1997, 8:1061-1069.
120. Hubbard N.E., Chen Q.J., Sickafoose L.K., Wood M.B., Gregg J.P., Abrahamsson N.M., Engelberg J.A., Walls J.E., Borowsky A.D. Transgenic mammary epithelial osteopontin (spp1) expression induces proliferation and alveologenesis. Genes Cancer 2013, 4:201-212.
121. Oates A.J., Barraclough R., Rudland P.S. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996, 13:97-104.
122. Feng F., Rittling S.R. Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Res. Treat. 2000, 63:71-79.
123. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., Guise T.A., Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
124. Tuck A.B., O'Malley F.P., Singhal H., Harris J.F., Tonkin K.S., Kerkvliet N., Saad Z., Doig G.S., Chambers A.F. Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer J. Int. Cancer 1998, 79:502-508.
125. Singhal H., Bautista D.S., Tonkin K.S., O'Malley F.P., Tuck A.B., Chambers A.F., Harris J.F. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 1997, 3:605-611.
126. McAllister S.S., Gifford A.M., Greiner A.L., Kelleher S.P., Saelzler M.P., Ince T.A., Reinhardt F., Harris L.N., Hylander B.L., Repasky E.A., Weinberg R.A. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008, 133:994-1005.
127. Chiquet-Ehrismann R., Mackie E.J., Pearson C.A., Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986, 47:131-139.
128. Ishihara A., Yoshida T., Tamaki H., Sakakura T. Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 1995, 1:1035-1041.
129. Ioachim E., Charchanti A., Briasoulis E., Karavasilis V., Tsanou H., Arvanitis D.L., Agnantis N.J., Pavlidis N. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur. J. Cancer 2002, 38:2362-2370.
130. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., Viale A., Olshen A.B., Gerald W.L., Massague J. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
131. O'Connell J.T., Sugimoto H., Cooke V.G., MacDonald B.A., Mehta A.I., LeBleu V.S., Dewar R., Rocha R.M., Brentani R.R., Resnick M.B., Neilson E.G., Zeisberg M., Kalluri R. VEGF-A and tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:16002-16007.
132. Ruan K., Bao S., Ouyang G. The multifaceted role of periostin in tumorigenesis. Cell. Mol. Life Sci.CMLS 2009, 66:2219-2230.
133. Liu A.Y., Zheng H., Ouyang G. Periostin, a multifunctional matricellular protein in inflammatory and tumor microenvironments. Matrix Biol. J. Int. Soc. Matrix Biol. 2014, 37:150-156.
134. Sriram R., Lo V., Pryce B., Antonova L., Mears A.J., Daneshmand M., McKay B., Conway S.J., Muller W.J., Sabourin L.A. Loss of periostin/OSF-2 in ErbB2/Neu-driven tumors results in androgen receptor-positive molecular apocrine-like tumors with reduced Notch1 activity. Breast Cancer Res. BCR 2015, 17:7.
135. Shao R., Bao S., Bai X., Blanchette C., Anderson R.M., Dang T., Gishizky M.L., Marks J.R., Wang X.F. Acquired expression of periostin by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol. Cell. Biol. 2004, 24:3992-4003.
136. Ishiba T., Nagahara M., Nakagawa T., Sato T., Ishikawa T., Uetake H., Sugihara K., Miki Y., Nakanishi A. Periostin suppression induces decorin secretion leading to reduced breast cancer cell motility and invasion. Sci. Report. 2014, 4:7069.
137. Puglisi F., Puppin C., Pegolo E., Andreetta C., Pascoletti G., D'Aurizio F., Pandolfi M., Fasola G., Piga A., Damante G., Di Loreto C. Expression of periostin in human breast cancer. J. Clin. Pathol. 2008, 61:494-498.
138. Zhang Y., Zhang G., Li J., Tao Q., Tang W. The expression analysis of periostin in human breast cancer. J. Surg. Res. 2010, 160:102-106.
139. Contie S., Voorzanger-Rousselot N., Litvin J., Clezardin P., Garnero P. Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. Int. J. Cancer J. Int. Cancer 2011, 128:352-360.
140. Ghajar C.M., Peinado H., Mori H., Matei I.R., Evason K.J., Brazier H., Almeida D., Koller A., Hajjar K.A., Stainier D.Y., Chen E.I., Lyden D., Bissell M.J. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 2013, 15:807-817.
141. Xu D., Xu H., Ren Y., Liu C., Wang X., Zhang H., Lu P. Cancer stem cell-related gene periostin: a novel prognostic marker for breast cancer. PLoS One 2012, 7.
142. Wang X., Liu J., Wang Z., Huang Y., Liu W., Zhu X., Cai Y., Fang X., Lin S., Yuan L., Ouyang G. Periostin contributes to the acquisition of multipotent stem cell-like properties in human mammary epithelial cells and breast cancer cells. PLoS One 2013, 8.
143. Kii I., Nishiyama T., Li M., Matsumoto K., Saito M., Amizuka N., Kudo A. Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J. Biol. Chem. 2010, 285:2028-2039.
144. Oskarsson T., Massague J. Extracellular matrix players in metastatic niches. EMBO J. 2012, 31:254-256.
145. Watkins G., Douglas-Jones A., Bryce R., Mansel R.E., Jiang W.G. Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. Prostaglandins Leukot. Essent. Fat. Acids 2005, 72:267-272.
146. Hsiao Y.H., Lien H.C., Hwa H.L., Kuo W.H., Chang K.J., Hsieh F.J. SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J. 2010, 16:305-308.
147. Witkiewicz A.K., Freydin B., Chervoneva I., Potoczek M., Rizzo W., Rui H., Brody J.R., Schwartz G.F., Lisanti M.P. Stromal CD10 and SPARC expression in ductal carcinoma in situ (DCIS) patients predicts disease recurrence. Cancer Biol. Ther. 2010, 10:391-396.
148. Graham J.D., Balleine R.L., Milliken J.S., Bilous A.M., Clarke C.L. Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content. Eur. J. Cancer 1997, 33:1654-1660.
149. Gerson K.D., Shearstone J.R., Maddula V.S., Seligmann B.E., Mercurio A.M. Integrin beta4 regulates SPARC protein to promote invasion. J. Biol. Chem. 2012, 287:9835-9844.
150. Adams J.C., Lawler J. The thrombospondins. Cold Spring Harb. Perspect. Biol. 2011, 3.
151. Yee K.O., Connolly C.M., Duquette M., Kazerounian S., Washington R., Lawler J. The effect of thrombospondin-1 on breast cancer metastasis. Breast Cancer Res. Treat. 2009, 114:85-96.
152. Albo D., Berger D.H., Wang T.N., Hu X., Rothman V., Tuszynski G.P. Thrombospondin-1 and transforming growth factor-beta l promote breast tumor cell invasion through up-regulation of the plasminogen/plasmin system. Surgery 1997, 122:493-499. (discussion 499-500).
153. Martin-Manso G., Calzada M.J., Chuman Y., Sipes J.M., Xavier C.P., Wolf V., Kuznetsova S.A., Rubin J.S., Roberts D.D. sFRP-1 binds via its netrin-related motif to the N-module of thrombospondin-1 and blocks thrombospondin-1 stimulation of MDA-MB-231 breast carcinoma cell adhesion and migration. Arch. Biochem. Biophys. 2011, 509:147-156.
154. del Pozo Martin Y., Park D., Ramachandran A., Ombrato L., Calvo F., Chakravarty P., Spencer-Dene B., Derzsi S., Caroline S., Hill E., Sahai I. Malanchi, mesenchymal cancer cell-stroma crosstalk promotes niche activation, epithelial reversion, and metastatic colonization. Cell Rep. 2015.
155. Fontana A., Filleur S., Guglielmi J., Frappart L., Bruno-Bossio G., Boissier S., Cabon F., Clezardin P. Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. Int. J. Cancer J. Int. cancer 2005, 116:686-691.
156. Byrne G.J., Hayden K.E., McDowell G., Lang H., Kirwan C.C., Tetlow L., Kumar S., Bundred N.J. Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int. J. Oncol. 2007, 31:1127-1132.
157. Green K.A., Lund L.R. ECM degrading proteases and tissue remodelling in the mammary gland. BioEssays News Rev. Mol. Cell. Develop. Biol. 2005, 27:894-903.
158. Bonnans C., Chou J., Werb Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell Biol. 2014, 15:786-801.
159. Gomes A.M., Stelling M.P., Pavao M.S. Heparan sulfate and heparanase as modulators of breast cancer progression. BioMed Res. Int. 2013, 2013.
160. Wiseman B.S., Sternlicht M.D., Lund L.R., Alexander C.M., Mott J., Bissell M.J., Soloway P., Itohara S., Werb Z. Site-specific inductive and inhibitory activities of MMP-2 and MMP-3 orchestrate mammary gland branching morphogenesis. J. Cell Biol. 2003, 162:1123-1133.
161. Duffy M.J., Maguire T.M., Hill A., McDermott E., O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. BCR 2000, 2:252-257.
162. Wolf K., Wu Y.I., Liu Y., Geiger J., Tam E., Overall C., Stack M.S., Friedl P. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat. Cell Biol. 2007, 9:893-904.
163. Friedl P., Gilmour D. Collective cell migration in morphogenesis, regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2009, 10:445-457.
164. Schenk S., Hintermann E., Bilban M., Koshikawa N., Hojilla C., Khokha R., Quaranta V. Binding to EGF receptor of a laminin-5 EGF-like fragment liberated during MMP-dependent mammary gland involution. J. Cell Biol. 2003, 161:197-209.
165. Koshikawa N., Giannelli G., Cirulli V., Miyazaki K., Quaranta V. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J. Cell Biol. 2000, 148:615-624.
166. Gilles C., Polette M., Coraux C., Tournier J.M., Meneguzzi G., Munaut C., Volders L., Rousselle P., Birembaut P., Foidart J.M. Contribution of MT1-MMP and of human laminin-5 gamma2 chain degradation to mammary epithelial cell migration. J. Cell Sci. 2001, 114:2967-2976.
167. Su G., Blaine S.A., Qiao D., Friedl A. Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. Cancer Res. 2008, 68:9558-9565.
168. Su G., Blaine S.A., Qiao D., Friedl A. Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J. Biol. Chem. 2007, 282:14906-14915.
169. Kelly T., Suva L.J., Nicks K.M., MacLeod V., Sanderson R.D. Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 2010, 25:1295-1304.
170. Leppa S., Saarto T., Vehmanen L., Blomqvist C., Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2004, 10:1057-1063.
171. Talvensaari-Mattila A., Paakko P., Hoyhtya M., Blanco-Sequeiros G., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 1998, 83:1153-1162.
172. Sternlicht M.D., Lochter A., Sympson C.J., Huey B., Rougier J.P., Gray J.W., Pinkel D., Bissell M.J., Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999, 98:137-146.
173. Ha H.Y., Moon H.B., Nam M.S., Lee J.W., Ryoo Z.Y., Lee T.H., Lee K.K., So B.J., Sato H., Seiki M., Yu D.Y. Overexpression of membrane-type matrix metalloproteinase-1 gene induces mammary gland abnormalities and adenocarcinoma in transgenic mice. Cancer Res. 2001, 61:984-990.
174. Gomes A.M., Bhat R., Correia A.L., Mott J.D., Ilan N., Vlodavsky I., Pavao M.S., Bissell M. Mammary branching morphogenesis requires reciprocal signaling by heparanase and MMP-14. J. Cell. Biochem. 2015, 116:1668-1679.
175. Zcharia E., Metzger S., Chajek-Shaul T., Friedmann Y., Pappo O., Aviv A., Elkin M., Pecker I., Peretz T., Vlodavsky I. Molecular properties and involvement of heparanase in cancer progression and mammary gland morphogenesis. J. Mammary Gland Biol. Neoplasia 2001, 6:311-322.
176. Vlodavsky I., Friedmann Y., Elkin M., Aingorn H., Atzmon R., Ishai-Michaeli R., Bitan M., Pappo O., Peretz T., Michal I., Spector L., Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis. Nat. Med. 1999, 5:793-802.
177. Cohen I., Pappo O., Elkin M., San T., Bar-Shavit R., Hazan R., Peretz T., Vlodavsky I., Abramovitch R. Heparanase promotes growth, angiogenesis and survival of primary breast tumors. Int. J. Cancer J. Int. Cancer 2006, 118:1609-1617.
178. Boyango I., Barash U., Naroditsky I., Li J.P., Hammond E., Ilan N., Vlodavsky I. Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res. 2014, 74:4504-4514.
179. Yang Y., Macleod V., Miao H.Q., Theus A., Zhan F., Shaughnessy J.D., Sawyer J., Li J.P., Zcharia E., Vlodavsky I., Sanderson R.D. Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumor growth and metastasis. J. Biol. Chem. 2007, 282:13326-13333.
180. Gawthorpe S., Brown J.E., Arif M., Nightingale P., Nevill A., Carmichael A.R. Heparanase and COX-2 expression as predictors of lymph node metastasis in large, high-grade breast tumors. Anticancer Res. 2014, 34:2797-2800.
181. Zhang L., Sullivan P.S., Goodman J.C., Gunaratne P.H., Marchetti D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 2011, 71:645-654.
182. Zhang L., Ngo J.A., Wetzel M.D., Marchetti D. Heparanase mediates a novel mechanism in lapatinib-resistant brain metastatic breast cancer. Neoplasia 2015, 17:101-113.
183. Cohen I., Maly B., Simon I., Meirovitz A., Pikarsky E., Zcharia E., Peretz T., Vlodavsky I., Elkin M. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2007, 13:4069-4077.
184. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
185. Burke M.A., Hutter D., Reshamwala R.P., Knepper J.E. Cathepsin L plays an active role in involution of the mouse mammary gland. Develop. Dyn. Off. Publ. Am. Assoc. Anat. 2003, 227:315-322.
186. Vasiljeva O., Korovin M., Gajda M., Brodoefel H., Bojic L., Kruger A., Schurigt U., Sevenich L., Turk B., Peters C., Reinheckel T. Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 2008, 27:4191-4199.
187. Sevenich L., Werner F., Gajda M., Schurigt U., Sieber C., Muller S., Follo M., Peters C., Reinheckel T. Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice. Oncogene 2011, 30:54-64.
188. Victor B.C., Anbalagan A., Mohamed M.M., Sloane B.F., Cavallo-Medved D. Inhibition of cathepsin B activity attenuates extracellular matrix degradation and inflammatory breast cancer invasion. Breast Cancer Res. BCR 2011, 13:R115.
189. Withana N.P., Blum G., Sameni M., Slaney C., Anbalagan A., Olive M.B., Bidwell B.N., Edgington L., Wang L., Moin K., Sloane B.F., Anderson R.L., Bogyo M.S., Parker B.S. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res. 2012, 72:1199-1209.
190. Littlewood-Evans A.J., Bilbe G., Bowler W.B., Farley D., Wlodarski B., Kokubo T., Inaoka T., Sloane J., Evans D.B., Gallagher J.A. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 1997, 57:5386-5390.
191. Le Gall C., Bellahcene A., Bonnelye E., Gasser J.A., Castronovo V., Green J., Zimmermann J., Clezardin P. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 2007, 67:9894-9902.
192. Duong Le T., Wesolowski G.A., Leung P., Oballa R., Pickarski M. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis. Mol. Cancer Ther. 2014, 13:2898-2909.
193. Irigoyen J.P., Munoz-Canoves P., Montero L., Koziczak M., Nagamine Y. The plasminogen activator system: biology and regulation. Cell. Mol. Life Sci.: CMLS 1999, 56:104-132.
194. Lund L.R., Bjorn S.F., Sternlicht M.D., Nielsen B.S., Solberg H., Usher P.A., Osterby R., Christensen I.J., Stephens R.W., Bugge T.H., Dano K., Werb Z. Lactational competence and involution of the mouse mammary gland require plasminogen. Development 2000, 127:4481-4492.
195. Tang L., Han X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomed. Pharmacother. = Biomed. Pharmacother. 2013, 67:179-182.
196. Han B., Nakamura M., Mori I., Nakamura Y., Kakudo K. Urokinase-type plasminogen activator system and breast cancer (review). Oncol. Rep. 2005, 14:105-112.
197. Look M.P., van Putten W.L., Duffy M.J., Harbeck N., Christensen I.J., Thomssen C., Kates R., Spyratos F., Ferno M., Eppenberger-Castori S., Sweep C.G., Ulm K., Peyrat J.P., Martin P.M., Magdelenat H., Brunner N., Duggan C., Lisboa B.W., Bendahl P.O., Quillien V., Daver A., Ricolleau G., Meijer-van Gelder M.E., Manders P., Fiets W.E., Blankenstein M.A., Broet P., Romain S., Daxenbichler G., Windbichler G., Cufer T., Borstnar S., Kueng W., Beex L.V., Klijn J.G., O'Higgins N., Eppenberger U., Janicke F., Schmitt M., Foekens J.A. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. 2002, 94:116-128.
198. Erler J.T., Bennewith K.L., Nicolau M., Dornhofer N., Kong C., Le Q.T., Chi J.T., Jeffrey S.S., Giaccia A.J. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006, 440:1222-1226.
199. Cox T.R., Rumney R.M., Schoof E.M., Perryman L., Hoye A.M., Agrawal A., Bird D., Latif N.A., Forrest H., Evans H.R., Huggins I.D., Lang G., Linding R., Gartland A., Erler J.T. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature 2015, 522:106-110.
200. Urakawa H., Nishida Y., Wasa J., Arai E., Zhuo L., Kimata K., Kozawa E., Futamura N., Ishiguro N. Inhibition of hyaluronan synthesis in breast cancer cells by 4-methylumbelliferone suppresses tumorigenicity in vitro and metastatic lesions of bone in vivo. Int. J.Cancer. J. Int. du cancer 2012, 130:454-466.
201. Kyutoku M., Taniyama Y., Katsuragi N., Shimizu H., Kunugiza Y., Iekushi K., Koibuchi N., Sanada F., Oshita Y., Morishita R. Role of periostin in cancer progression and metastasis: inhibition of breast cancer progression and metastasis by anti-periostin antibody in a murine model. Int. J. Mol. Med. 2011, 28:181-186.
202. Lee Y.J., Kim I.S., Park S.A., Kim Y., Lee J.E., Noh D.Y., Kim K.T., Ryu S.H., Suh P.G. Periostin-binding DNA aptamer inhibits breast cancer growth and metastasis. Mol. therapy: J. Am. Soc. Gene Ther. 2013, 21:1004-1013.
203. De Santis R., Albertoni C., Petronzelli F., Campo S., D'Alessio V., Rosi A., Anastasi A.M., Lindstedt R., Caroni N., Arseni B., Chiodi P., Verdoliva A., Cassani G., Chinol M., Paganelli G., Carminati P. Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody. Clin. Cancer Res.: an official journal of the American Association for Cancer Research 2006, 12:2191-2196.
204. Petronzelli F., Pelliccia A., Anastasi A.M., D'Alessio V., Albertoni C., Rosi A., Leoni B., De Angelis C., Paganelli G., Palombo G., Dani M., Carminati P., De Santis R. Improved tumor targeting by combined use of two antitenascin antibodies. Clin. Cancer Res.: an official journal of the American Association for Cancer Research 2005, 11:7137s-7145s.
205. Marlind J., Kaspar M., Trachsel E., Sommavilla R., Hindle S., Bacci C., Giovannoni L., Neri D. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2008, 14:6515-6524.
206. Rousseau C., Ruellan A.L., Bernardeau K., Kraeber-Bodere F., Gouard S., Loussouarn D., Sai-Maurel C., Faivre-Chauvet A., Wijdenes J., Barbet J., Gaschet J., Cherel M., Davodeau F. Syndecan-1 antigen, a promising new target for triple-negative breast cancer immuno-PET and radioimmunotherapy. A Preclinical Study on MDA-MB-468 Xenograft Tumors, EJNMMI Research 2011, 1:20.
207. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
208. Park C.C., Zhang H., Pallavicini M., Gray J.W., Baehner F., Park C.J., Bissell M.J. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 2006, 66:1526-1535.
209. Khalili P., Arakelian A., Chen G., Plunkett M.L., Beck I., Parry G.C., Donate F., Shaw D.E., Mazar A.P., Rabbani S.A. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Ther. 2006, 5:2271-2280.
210. Harms J.F., Welch D.R., Samant R.S., Shevde L.A., Miele M.E., Babu G.R., Goldberg S.F., Gilman V.R., Sosnowski D.M., Campo D.A., Gay C.V., Budgeon L.R., Mercer R., Jewell J., Mastro A.M., Donahue H.J., Erin N., Debies M.T., Meehan W.J., Jones A.L., Mbalaviele G., Nickols A., Christensen N.D., Melly R., Beck L.N., Kent J., Rader R.K., Kotyk J.J., Pagel M.D., Westlin W.F., Griggs D.W. A small molecule antagonist of the alpha(v)beta3 integrin suppresses MDA-MB-435 skeletal metastasis. Clin. Exp. Metastasis 2004, 21:119-128.
211. Zhao Y., Bachelier R., Treilleux I., Pujuguet P., Peyruchaud O., Baron R., Clement-Lacroix P., Clezardin P. Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. Cancer Res. 2007, 67:5821-5830.
212. Wu Y.J., Muldoon L.L., Gahramanov S., Kraemer D.F., Marshall D.J., Neuwelt E.A. Targeting alphaV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. J. Neuro-Oncol. 2012, 110:27-36.
213. Bauerle T., Komljenovic D., Merz M., Berger M.R., Goodman S.L., Semmler W. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE-MRI in a longitudinal in vivo study. Int. J. Cancer J. Int. Cancer 2011, 128:2453-2462.
214. Kim S.H., Turnbull J., Guimond S. Extracellular matrix and cell signalling: the dynamic cooperation of integrin, proteoglycan and growth factor receptor. J. Endocrinol. 2011, 209:139-151.
215. Finn R.S. Targeting Src in breast cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. ESMO 2008, 19:1379-1386.
216. Zhang X.H., Wang Q., Gerald W., Hudis C.A., Norton L., Smid M., Foekens J.A., Massague J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16:67-78.
217. Hiscox S., Nicholson R.I. Src inhibitors in breast cancer therapy. Expert Opin. Ther. Targets 2008, 12:757-767.
218. Golubovskaya V.M., Zheng M., Zhang L., Li J.L., Cance W.G. The direct effect of focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression and human MCF-7 breast cancer cell tumorigenesis. BMC Cancer 2009, 9:280.
219. Dunn K.B., Heffler M., Golubovskaya V.M. Evolving therapies and FAK inhibitors for the treatment of cancer. Anti Cancer Agents Med. Chem. 2010, 10:722-734.
220. Cox T.R., Erler J.T. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis. Model. Mech. 2011, 4:165-178.
221. Dredge K., Hammond E., Handley P., Gonda T.J., Smith M.T., Vincent C., Brandt R., Ferro V., Bytheway I. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. B. J. Cancer 2011, 104:635-642.
222. Jensen A.B., Wynne C., Ramirez G., He W., Song Y., Berd Y., Wang H., Mehta A., Lombardi A. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin. Breast Cancer 2010, 10:452-458.
223. Coussens L.M., Fingleton B., Matrisian L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002, 295:2387-2392.
224. Mack G.S., Marshall A. Lost in migration. Nat. Biotechnol. 2010, 28:214-229.
225. Ager E.I., Kozin S.V., Kirkpatrick N.D., Seano G., Kodack D.P., Askoxylakis V., Huang Y., Goel S., Snuderl M., Muzikansky A., Finkelstein D.M., Dransfield D.T., Devy L., Boucher Y., Fukumura D., Jain R.K. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. J. Natl. Cancer Inst. 2015, 107.
226. Neill T., Schaefer L., Iozzo R.V. Instructive roles of extracellular matrix on autophagy. Am. J. Pathol. 2014, 184:2146-2153.
227. Perletti G., Concari P., Giardini R., Marras E., Piccinini F., Folkman J., Chen L. Antitumor activity of endostatin against carcinogen-induced rat primary mammary tumors. Cancer Res. 2000, 60:1793-1796.
228. Ren Z., Wang Y., Jiang W., Dai W., Jiang Y. Anti-tumor effect of a novel soluble recombinant human endostatin: administered as a single agent or in combination with chemotherapy agents in mouse tumor models. PLoS One 2014, 9.
229. Sun J., Deng L., Duan Y., Chen F., Wang X., Li D., Chen Z. Inhibitory effect of endostatin combined with paclitaxel-cisplatin on breast cancer in xenograft-bearing mice. Exp. Ther. Med. 2012, 3:159-164.
230. Chen J., Yao Q., Li D., Zhang J., Wang T., Yu M., Zhou X., Huan Y., Wang J., Wang L. Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study. BMC Cancer 2013, 13:248.